Nonmutational compensation of the fitness cost of antibiotic resistance in mycobacteria by overexpression of tlyA rRNA methylase

RNA

Volumn 22, Issue 12, 2016, Pages 1836-1843

  Freihofer, Pietro ^a   Akbergenov, Rashid ^a   Teo, Youjin ^a   Juskeviciene, Reda ^a   Andersson, Dan I ^b   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibiotic resistance; Compensation; Fitness; Mycobacterium tuberculosis; Rrna methylation; Tlya

Indexed keywords

AMIKACIN; CAPREOMYCIN; RIBOSOME RNA; TUBERACTINOMYCIN; VIOMYCIN; BACTERIAL PROTEIN; RNA 16S; RNA 23S; TLYA PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; COMPENSATION; CONTROLLED STUDY; DOWN REGULATION; DRUG COST; FITNESS; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; CELL FREE SYSTEM; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; MYCOBACTERIUM; PROTEIN SYNTHESIS;

BACTERIAL PROTEINS; CELL-FREE SYSTEM; DRUG RESISTANCE, BACTERIAL; MUTATION; MYCOBACTERIUM; PROTEIN BIOSYNTHESIS; RNA, RIBOSOMAL, 16S; RNA, RIBOSOMAL, 23S;

EID: 84999106920     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.057257.116     Document Type: Article

References (34)

1. Akbergenov R, Shcherbakov D, Matt T, Duscha S, Meyer M, Wilson DN, Bottger EC. 2011. Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin. Antimicrob Agents Chemother 55: 4712-4717.
2. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8: 260-271.
3. Andersson DI, Levin BR. 1999. The biological cost of antibiotic resistance. Curr Opin Microbiol 2: 489-493.
4. Baym M, Stone LK, Kishony R. 2016. Multidrug evolutionary strategies to reverse antibiotic resistance. Science 351: Aad3292.
5. Beringer M, Bruell C, Xiong L, Pfister P, Bieling P, Katunin VI, Mankin AS, Bottger EC, Rodnina MV. 2005. Essential mechanisms in the catalysis of peptide bond formation on the ribosome. J Biol Chem 280: 36065-36072.
6. Bottger EC, Springer B. 2008. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr 167: 141-148.
7. Bottger EC, Springer B, Pletschette M, Sander P. 1998. Fitness of antibiotic- resistant microorganisms and compensatory mutations. Nat Med 4: 1343-1344.
8. Bruell CM, Eichholz C, Kubarenko A, Post V, Katunin VI, Hobbie SN, Rodnina MV, Bottger EC. 2008. Conservation of bacterial protein synthesis machinery: initiation and elongation in Mycobacterium smegmatis. Biochemistry 47: 8828-8839.
9. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. 2012. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44: 106-110.
10. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, et al. 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38: 516-528.
11. Felix MA, Barkoulas M. 2015. Pervasive robustness in biological systems. Nat Rev Genet 16: 483-496.
12. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rusch- Gerdes S, Niemann S. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 53: 3353-3356.
13. Ho WC, Zhang J. 2016. Adaptive genetic robustness of Escherichia coli metabolic fluxes. Mol Biol Evol 33: 1164-1176.
14. Hobbie SN, Bruell C, Kalapala S, Akshay S, Schmidt S, Pfister P, Bottger EC. 2006. A genetic model to investigate drug-Target interactions at the ribosomal decoding site. Biochimie 88: 1033-1043.
15. Hobbie SN, Kalapala SK, Akshay S, Bruell C, Schmidt S, Dabow S, Vasella A, Sander P, Bottger EC. 2007. Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria. Nucleic Acids Res 35: 6086-6093.
16. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S. 2006. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2′- O-methylations in 16S and 23S rRNAs. Mol Cell 23: 173-182.
17. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. 2009. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 53: 5064-5068.
18. Maus CE, Plikaytis BB, Shinnick TM. 2005a. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 3192-3197.
19. Maus CE, Plikaytis BB, Shinnick TM. 2005b. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 571-577.
20. McClatchy JK, Kanes W, Davidson PT, Moulding TS. 1977. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 58: 29-34.
21. Meftahi N, Namouchi A, Mhenni B, Brandis G, Hughes D, Mardassi H. 2016. Evidence for the critical role of a secondary site rpoB mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain. J Antimicrob Chemother 71: 324-332.
22. Michel JB, Yeh PJ, Chait R, Moellering RC Jr, Kishony R. 2008. Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci 105: 14918-14923.
23. Monshupanee T, Johansen SK, Dahlberg AE, Douthwaite S. 2012. Capreomycin susceptibility is increased by TlyA-directed 2′-Omethylation on both ribosomal subunits. Mol Microbiol 85: 1194-1203.
24. Munck C, Gumpert HK, Wallin AI, Wang HH, Sommer MO. 2014. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci Transl Med 6: 262ra156.
25. Naseeb S, Carter Z, Minnis D, Donaldson I, Zeef L, Delneri D. 2016. Widespread impact of chromosomal inversions on gene expression uncovers robustness via phenotypic buffering. Mol Biol Evol 33: 1679-1696.
26. Olivares J, Alvarez-Ortega C, Martinez JL. 2014. Metabolic compensation of fitness costs associated with overexpression of the multidrug efflux pump MexEF-OprN in Pseudomonas aeruginosa. Antimicrob Agents Chemother 58: 3904-3913.
27. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-Time RT-PCR. Nucleic Acids Res 29: e45.
28. Reeves AZ, Campbell PJ, Willby MJ, Posey JE. 2015. Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59: 444-449.
29. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Bottger EC. 2002. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 46: 1204-1211.
30. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Bottger EC. 2010. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 77: 830-840.
31. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE III, Stover CK. 1996. Compensatory ahpC gene expression in isoniazidresistant Mycobacterium tuberculosis. Science 272: 1641-1643.
32. Sirgel FA, Tait M, Warren RM, Streicher EM, Bottger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, et al. 2012. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 18: 193-197.
33. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Bottger EC. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 47: 1773-1780.
34. Stanley RE, Blaha G, Grodzicki RL, Strickler MD, Steitz TA. 2010. The structures of the anti-Tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat Struct Mol Biol 17: 289-293.